华海药业(600521) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥2,119,347,156.66, representing a year-on-year increase of 10.76%[2] - Net profit attributable to shareholders for Q3 2024 was ¥282,702,104.64, an increase of 85.09% compared to the same period last year[2] - The basic earnings per share for Q3 2024 was ¥0.19, reflecting a growth of 72.73% year-on-year[3] - The company reported a net profit attributable to shareholders for the year-to-date of ¥1,031,268,135.45, which is a 42.92% increase compared to the previous year[2] - Total operating revenue for the first three quarters of 2024 reached CNY 7,247,654,219.70, an increase of 16.77% compared to CNY 6,207,564,556.19 in the same period of 2023[15] - The company reported a net profit of CNY 1,037,247,794.71 for the first three quarters, up from CNY 713,177,829.99, representing a growth of 45.43%[16] - The company's earnings per share (EPS) for the first three quarters was CNY 0.71, compared to CNY 0.50 in the same period last year, an increase of 42.00%[16] - The net profit for the first three quarters of 2024 was CNY 1,717,362,329.19, representing a growth of 18.4% from CNY 1,450,746,344.80 in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥19,555,189,777.33, showing a 5.14% increase from the end of the previous year[3] - As of September 30, 2024, current assets totaled RMB 7,980,130,228.56, an increase from RMB 7,621,698,796.25 at the end of 2023, representing a growth of approximately 4.7%[11] - Total assets amounted to RMB 19,555,189,777.33, compared to RMB 18,599,969,612.84 at the end of 2023, marking a growth of approximately 5.1%[12] - Total liabilities were RMB 7,834,994,796.58, up from RMB 7,662,465,617.99, indicating an increase of about 2.2%[12] - The total liabilities of the company reached CNY 10,600,241,308.65, compared to CNY 10,348,854,672.57, reflecting an increase of 2.43%[15] - The total liabilities decreased to CNY 7,035,259,874.62 from CNY 7,713,638,601.41, reflecting a reduction of approximately 8.8%[20] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,877,383,787.13, up 29.32% year-on-year[2] - The total cash inflow from operating activities for the first three quarters of 2024 was approximately CNY 7.61 billion, an increase of 11.4% compared to CNY 6.82 billion in the same period of 2023[17] - The net cash flow from operating activities reached CNY 1.88 billion, up 29.4% from CNY 1.45 billion year-on-year[17] - Cash inflow from financing activities increased significantly to CNY 4.01 billion, compared to CNY 2.46 billion in the previous year, marking a 62.9% increase[18] - The cash flow from operating activities generated a net amount of CNY 1,324,459,541.71, slightly up from CNY 1,278,345,016.24 in the same period last year[23] - The cash inflow from operating activities totaled CNY 5,267,149,429.69, compared to CNY 4,505,701,493.03 in the previous year, reflecting an increase of 16.9%[23] Investments and Expenditures - The company has invested RMB 862,737,456.92 in development expenditures, up from RMB 796,284,582.75, indicating an increase of approximately 8.3%[12] - Research and development expenses totaled CNY 687,452,738.14, slightly increasing from CNY 667,445,298.33, indicating a focus on innovation[15] - Research and development expenses for the first three quarters of 2024 were CNY 291,999,854.23, showing a slight decrease from CNY 293,032,261.11 in 2023[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 55,692[7] - The company has not reported any significant changes in the top 10 shareholders due to the transfer of shares[9] Market Position and Strategy - The company has introduced new products that are gradually increasing in volume, contributing to improved market share[5] - The company is actively expanding its global sales network, which has effectively enhanced its market penetration[5]